Physician profile
Chebli Mrad
NPI 1881078715
$1,584.02
in general payments reported to CMS, 2019-2025
31 companies · $805 in 2025
The $805 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.32 · 2022: $152 · 2023: $147 · 2024: $468 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $929 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $400 · Education: $90.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $929.46 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $400.00 |
| Education | $90.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Deciphera Pharmaceuticals INC. | $437.83 | 2023-2025 | Romvimza, Qinlock |
| Astrazeneca Pharmaceuticals LP | $187.44 | 2022-2025 | Tagrisso, Lynparza |
| Novartis Pharmaceuticals Corporation | $93.96 | 2021-2023 | |
| Daiichi Sankyo INC. | $83.29 | 2024-2025 | Enhertu, Datroway |
| Seagen INC. | $74.99 | 2024 | |
| Glaxosmithkline, LLC. | $68.92 | 2024-2025 | Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $65.97 | 2024-2025 | Iclusig, Ninlaro |
| Aveo Pharmaceuticals, INC. | $65.53 | 2025 | |
| Sobi, INC | $39.74 | 2024-2025 | |
| Springworks Therapeutics, INC. | $39.00 | 2025 | Ogsiveo |
| Merck Sharp & Dohme LLC | $34.78 | 2023 | Keytruda, Lynparza |
| Eisai INC. | $34.77 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $32.99 | 2024-2025 | Opdualag, Opdivo |
| Genzyme Corporation | $32.37 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $25.42 | 2024 | Libtayo |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tersera Therapeutics LLC | $22.15 | 2024 | Zoladex |
| Pfizer INC. | $22.04 | 2025 | |
| Genentech, INC. | $21.33 | 2023 | Tecentriq |
| Tempus Ai, INC | $21.21 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $20.83 | 2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $18.98 | 2023 | Xtandi |
| Lilly USA, LLC | $17.32 | 2022 | |
| Genentech USA, INC. | $16.76 | 2023 | Lunsumio, Polivy |
| Janssen Biotech, INC. | $16.13 | 2025 | Rybrevant |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Incyte Corporation | $15.62 | 2024 | Jakafi |
| Array Biopharma INC | $15.23 | 2024 | Mektovi, Braftovi, Tukysa |
| Amgen INC. | $15.00 | 2022 | |
| Foundation Medicine, INC. | $14.57 | 2022 | |
| Stemline Therapeutics INC. | $13.86 | 2024 | Orserdu |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chebli Mrad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.